Intracameral more effective than subconjunctival cefuroxime

Article

Intracameral cefuroxime is a safe alternative to subconjunctival cefuroxime and leads to a lower rate of endophthalmitis, claims a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

Intracameral cefuroxime is a safe alternative to subconjunctival cefuroxime and leads to a lower rate of endophthalmitis, claims a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

Patrick Yu-Wai-Man and colleagues at the Sunderland Eye Infirmary, UK, performed a retrospective analysis of all presumed infectious endophthalmitis cases from January 1, 2000, to December 31, 2006, and compared the rate of presumed infectious endophthalmitis in patients receiving subconjunctival cefuroxime with those receiving intracameral cefuroxime at the end of surgery.

The study, whose purpose was to compare the efficacy of intracameral cefuroxime versus subconjunctival cefuroxime in reducing the rate of endophthalmitis after cataract surgery, included 36 743 phacoemulsification cataract procedures, with a mean rate of presumed infectious endophthalmitis of 0.95 per 1000 cases. The incidence of endophthalmitis was significantly higher in the subconjunctival cefuroxime group than in the intracameral cefuroxime group.

Overall, the researchers found that intracameral cefuroxime was a safe alternative to subconjunctival cefuroxime and led to a lower rate of endophthalmitis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.